

Table S1. Patient demographics and baseline characteristics of patients treated at the dose of 30 mg/week of everolimus.

Characteristics	
Number of patients enrolled	N=3
Age, median (year); [range]	61 [55-62]
Gender, n (%)	
Male	3 (100)
WHO performance status, n (%)	
0	2 (66.7)
1	1 (33.3)
Disease stage, n (%)	
IVa	2 (66.7)
IVb	1 (33.3)
T stage, n (%)	
2	2 (66.7)
4a	1 (33.3)
N stage, n (%)	
2b	1 (33.3)
2c	1 (33.3)
3	1 (33.3)
Primary site, n (%)	
Oropharynx	2 (66.7)
Oral cavity	1 (33.3)